IXI Stock Overview
Provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
IXICO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.12 |
| 52 Week High | UK£0.13 |
| 52 Week Low | UK£0.064 |
| Beta | 0.68 |
| 1 Month Change | 2.13% |
| 3 Month Change | 26.32% |
| 1 Year Change | 14.29% |
| 3 Year Change | -75.26% |
| 5 Year Change | -85.71% |
| Change since IPO | -79.66% |
Recent News & Updates
Recent updates
Is IXICO plc (LON:IXI) Potentially Undervalued?
Sep 30
Is It Time To Consider Buying IXICO plc (LON:IXI)?
Apr 13If You Like EPS Growth Then Check Out IXICO (LON:IXI) Before It's Too Late
Feb 25Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Nov 20Should You Think About Buying IXICO plc (LON:IXI) Now?
Oct 25Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Aug 11Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Apr 17IXICO plc (LON:IXI) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Mar 24At UK£1.04, Is It Time To Put IXICO plc (LON:IXI) On Your Watch List?
Mar 22Does IXICO's (LON:IXI) Statutory Profit Adequately Reflect Its Underlying Profit?
Feb 22Did Business Growth Power IXICO's (LON:IXI) Share Price Gain of 146%?
Feb 01
Will Weakness in IXICO plc's (LON:IXI) Stock Prove Temporary Given Strong Fundamentals?
Jan 09I Ran A Stock Scan For Earnings Growth And IXICO (LON:IXI) Passed With Ease
Dec 22Who Has Been Selling IXICO plc (LON:IXI) Shares?
Dec 04What Does IXICO plc's (LON:IXI) Share Price Indicate?
Jul 06Shareholder Returns
| IXI | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | -5.5% | 0.1% |
| 1Y | 14.3% | -13.1% | 9.0% |
Return vs Industry: IXI exceeded the UK Life Sciences industry which returned -13.1% over the past year.
Return vs Market: IXI exceeded the UK Market which returned 9% over the past year.
Price Volatility
| IXI volatility | |
|---|---|
| IXI Average Weekly Movement | 7.9% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: IXI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: IXI's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 81 | Bram Goorden | ixico.com |
IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company’s technologies comprise Assessa, an online digital platform for clinics; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer.
IXICO plc Fundamentals Summary
| IXI fundamental statistics | |
|---|---|
| Market cap | UK£11.12m |
| Earnings (TTM) | -UK£2.00m |
| Revenue (TTM) | UK£5.77m |
1.9x
P/S Ratio-5.6x
P/E RatioIs IXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IXI income statement (TTM) | |
|---|---|
| Revenue | UK£5.77m |
| Cost of Revenue | UK£3.06m |
| Gross Profit | UK£2.71m |
| Other Expenses | UK£4.71m |
| Earnings | -UK£2.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 47.02% |
| Net Profit Margin | -34.70% |
| Debt/Equity Ratio | 0% |
How did IXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 03:20 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
IXICO plc is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Donnellan | Cavendish |
| Christopher Donnellan | Cavendish Historical (Cenkos Securities) |
| Vadim Alexandre Khalil | Daniel Stewart & Company |